A&D Pharma, the biggest domestic pharmaceutical group, inthe first half of this year saw its income rise by 90% to 17.5meuros and its turnover go up by 30% to 303.2m euros. The figuresare among the best companies in the economy have so far reported,in the context where Romania is now in recession and mostbusinesses are struggling to survive. "In 2008 we carried outextensive restructuring and we embarked upon an ongoing process toboost efficiency. We more strongly integrated distribution withpharmacies, but part of the income increase is also linked toturnover growth," said Robert Popescu, A&D Pharma CEO. Turnovergrowth also came amid pharmaceutical market expansion by 19% in H1,in line with A&D Pharma, quoting Cegedim data. "We managed togenerate profit, but there are some major risks of not cashing inmoney from the market because of which part of this income mayremain on paper. (…)," Robert Popescu also said. The company'sstock is traded on the LSE. Since listing, in 2006, the stock hasposted a downward trend. "There are question marks about theutility of listing". "We are the biggest Romanian pharmaceuticalcompany, but we are probably not big enough in London to attractinterest. Floatation in itself was a success," said Popescu.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
